Overlapping symptoms and co-infections may result in incorrect diagnosis and inadequate treatment, leading to persistent and recurring vaginal infections.1
Millions of women with vulvovaginitis receive inadequate treatment.
A US community practice study showed that 4 out of 10 women didn’t receive an appropriate diagnosis and treatment for their vaginitis symptoms after an initial physician visit, which led to 4 out of 10 women having to schedule a new appointment because of persistent symptoms.2
On the other hand, many women attempt to self-diagnose but 1 out of 2 fails to self-medicate appropriately, leading to persistent vaginitis.3
Misdiagnosis
4 out of 10 women did not receive appropriate diagnosis and treatment for vaginitis symptoms.2
High repeat visits
Frequency of return visits for persistent symptoms was as high as 42% among women with vaginitis.2
Incorrect diagnosis and inadequate treatment may lead to recurrent and treatment-resistant infections.
Diagnosing vaginitis is challenging due to overlapping symptoms and co-infection from multiple organisms.1,4-9
Incorrect diagnosis and treatment is common and can lead to recurring infections, or worse, resistant infections.10-12 More than 50% of women treated for bacterial vaginosis will have a recurrent infection,10 while 10 to 15% of women with recurrent vulvovaginal candidiasis will find out that they are infected with a resistant strain.12
More than 50% of women treated for BV will have a recurrent infection.10
10–15% of women with recurrent vulvovaginal candidiasis have a resistant yeast strain.12
Accurate diagnosis can be achieved with the BD MAX™ Vaginal Panel.
By identifying the root cause of vaginitis symptoms, you can help avoid recurrence.
Clear diagnosis of BV, VVC, and TV is critical to:
Ensure appropriate treatment regimens13
Decrease the risk of associated complications4
Decrease the risk of contracting STIs4
Decrease the unnecessary use of treatments13
Decrease the risk of resistance to treatment13
Decrease health resources utilization4
BD MAX™ Vaginal Panel is the first FDA-cleared microbiome-based, PCR assay that directly detects bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and Trichomonas vaginalis (TV), the 3 most common infectious causes of vaginitis in 1 test.9,14,15
1. Schwebke JR et al. J Clin Microbiol. 2020;58(2):e01643-19.
2. Hillier SL et al. Clin Infect Dis. 2021;72(9):1538–43.
3. Ryan-Wenger NA et al. Nurs Res. 2010;59(1):2–10.
4. Brown H and Drexler M. Popul Health Manag. 2020;23(S1):S3–12.
5. Paladine HL and Desai UA. Am Fam Physician. 2018;97(5):321–9.
6. Bacterial Vaginosis CDC Fact Sheet, CDC. Accessed July 11, 2022.
7. Vulvovaginal Candidiasis, CDC. Accessed July 11, 2022.
8. Trichomoniasis CDC Fact Sheet, CDC. Accessed July 11, 2022.
9. Gaydos CA et al. Obstet Gynecol. 2017;130(1):181–9.
10. Faught BM and Reyes S. J Women’s Health. 2019;28(9):1218–26.
11. Thompson A et al. Eur J Clin Microbiol Infect Dis. 2020;39(1):39–44.
12. Miller JM et al. Clin Infect Dis. 2018;67(6):e1–e94.
13. Broache M et al. Obstet Gynecol. 2021;138:853–9.
14. Schwebke JR et al. J Clin Microbiol. 2018;56:e00252-18.
15. BD MAX™ Vaginal Panel Package Insert (P0258).
Learn more about our BD Women’s Health solutions
This form is only intended for use by healthcare professionals seeking additional information about BD products and solutions. Patients seeking health and treatment information should contact their healthcare professional and can find additional resources from ACOG and the American Cancer Society.
Do not submit protected health information (PHI) or patient information (PII) through this form. If you do submit PHI or PII, your question may not be answered, as the information will be deleted to protect your privacy.
